Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors Editorial


Authors: Castillo, J. J.; Autore, F.; Berinstein, N. L.; Branagan, A. R.; Dimopoulos, M. A.; Fernandez de Larrea, C.; Ferrero, S.; Kapoor, P.; Kastritis, E.; Khwaja, J.; Minnema, M. C.; Qiu, L.; Seymour, J. F.; Vos, J. M. I.; Patterson, C. J.; Buske, C.; Matous, J. V.; Treon, S. P.; Palomba, M. L.
Title: Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
Title Series: Seminars in Hematology
Abstract: Over the last decade, covalent Bruton tyrosine kinase (BTK) inhibitors have become a standard option for treating patients with symptomatic Waldenström Macroglobulinemia (WM) in the frontline or relapsed settings. However, the definition of intolerance and resistance to covalent BTK inhibitors has not been established. Understanding the best approaches to managing such patients is crucial to avoiding premature abandonment of effective therapy or pursuing futile therapies unlikely to be effective in controlling symptomatic disease progression. With the advent of noncovalent BTK inhibitors and BCL2 antagonists, in addition to clinical trials evaluating phospholipid-drug conjugates, antibody-drug conjugates, and bispecific antibodies, the present Consensus Panel 5 aims to establish working definitions for intolerance and resistance to covalent BTK inhibitors, as well as provide strategies to identify and manage these issues not infrequently encountered in clinical practice. © 2025 The Authors
Keywords: cancer chemotherapy; unclassified drug; neutropenia; hypertension; conference paper; rituximab; consensus; infection; anemia; bleeding; thrombocytopenia; withdrawal syndrome; waldenstroem macroglobulinemia; drug hypersensitivity; rash; cancer control; gastrointestinal disease; atrial fibrillation; disease exacerbation; heart ventricle arrhythmia; musculoskeletal disease; drug conjugation; heart arrest; resistance; phospholipid; clinical trial (topic); waldenstrom macroglobulinemia; intolerance; ibrutinib; human; venetoclax; acalabrutinib; bruton tyrosine kinase inhibitor; tirabrutinib; zanubrutinib; pirtobrutinib; epcoritamab; loncastuximab tesirine; nx 5948; nemtabrutinib; orelabrutinib; sonrotoclax; covalent btk inhibitors; catadegbrutinib; iopofosine i 131; zelebrudomide
Journal Title: Seminars in Hematology
Volume: 62
ISSN: 0037-1963
Publisher: W.B. Saunders Co-Elsevier Inc.  
Date Published: 2025-04-01
Start Page: 113
End Page: 119
Language: English
DOI: 10.1053/j.seminhematol.2025.04.004
PROVIDER: scopus
PUBMED: 40379542
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Maria Lia Palomba
    442 Palomba